The report has been developed as a part of IHE’s partnership in the VINNOVA-funded innovation milieu Test Bed Sweden Precision Health Cancer.

Testbed Sweden Precision Cancer is attending the PRIME-ROSE kick-off in Oslo right now!

We are looking forward to participating at the Nordic Precision Cancer Medicine conference in Oslo during next week.

Testbed Sweden for Precision Health in Cancer is a system demonstrator of how to introduce concrete precision medicine activities into the Swedish healthcare system in a way that is sustainable and just.

Vision Zero Cancer and Testbed Sweden Precision Health Cancer organized two events in Almedalen 2023. Almedalen takes place each year in Sweden in the city of Visby at the island of Gotland and is the world's largest democratic meeting place for social issues.

PRIME-ROSE - A European precision cancer medicine trial network and implementation initiative funded by the EU Cancer Mission. The project was approved by the European Commission om April 23 2023.

We are excited to be part of the growing DLCT (DRUP-Like Clinical Trial) Community and are looking forward to start working on the implementation of precision medicine for all patients in Europe!

Combining Expertise Across Borders to Promote Precision Cancer Medicine in Europe. PRIME-ROSE is a Horizon Europe Mission on Cancer project with 24 partners from altogether 18 European countries. Moreover, PRIME-ROSE is part of the Cancer Mission cluster of projects on Diagnosis and Treatment.

Vision Zero Cancer and Testbed Sweden Precision Health Cancer are organizing two events in Almedalen 2023. Almedalen takes place each year in Sweden in the city of Visby at the island of Gotland and is the world's largest democratic meeting place for social issues.

Great meeting with European Medicines Agency discussing the PRIME-ROSE and PCM4EU - Personalised Cancer Medicine for all EU citizens projects!

PRIME-ROSE - A European precision cancer medicine trial network and implementation initiative funded by the EU Cancer Mission. The project was approved by the European Commission om April 23 2023.